Microchannel FT reactor rated up to 800 bpd (~30 kt/a) per unit, designed to reduce reactor count and support 100+ kt/a SAF and e‑fuel projects.
Dual Ang‑2/VEGF‑A inhibitor delivered vision gains, lesion regression and dosing intervals up to 20 weeks for most patients in a two‑year Asian PCV trial.
Cost cuts and an equity valuation gain lift results; advancing ISCC EU recycled-fuel certification in China and selecting Ghent for a commercial-scale SAF facility.
Three Phase III trials will test DLL3-targeting obrixtamig in SCLC and epNEC, and HER2 TKI zongertinib as adjuvant therapy in resectable HER2‑mutant NSCLC.
IPO of 40M H‑shares in Hong Kong raised ~$75M and implied ~US$750M market cap; JV reports annual revenue of roughly $77–87M and targets waste‑derived ethanol‑to‑SAF.
TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.
BEHOLD-1 phase I: Mo-Rez (B7-H4 ADC) active across expression levels; manageable hematologic toxicity and nausea. 5.8 mg/kg recommended; five Phase III trials planned 2026
Revenue +12.5% to 9,371 bln KZT; EBITDA +19.6% to 2,393 bln; net profit down to 1,072 bln; net debt cut to 375 bln; production +10%; FCF +2.8%
Triple-agonist UBT251 (GLP-1/GIP/glucagon) induced up to 9.8% weight loss, improved BP and lipids vs placebo/semaglutide. Safety consistent with triple-G class; global phase-2 and China phase-3 planned
Risvutatug rezetecan, a B7-H3–targeted ADC, showed durable responses in extensive‑stage SCLC in phase I ARTEMIS‑001; global phase III in relapsed ES‑SCLC is underway.
